The approval is supported by bioequivalence data assessing the once-daily extended-release formulation to twice-daily immediate-release ruxolitinib in healthy participants.
Steroid therapy is the first-line treatment for graft-versus-host disease (GVHD). If GVHD does not respond to initial therapies, doctors may consider chemotherapy, monoclonal antibodies, and other ...
Graft-versus-host disease (GVHD) is common, yet it is poorly understood and its symptoms can be difficult to recognize. The National Comprehensive Cancer Network (NCCN) has published a new resource ...
A new review article highlights some of the newest therapies available to treat graft-versus-host disease (GVHD), but the authors say there is insufficient data to draw broad conclusions. Patients ...
Prophylactic administration of obinutuzumab, a B-cell-depleting antibody, reduces the incidence of corticosteroid-requiring chronic graft-vs-host disease (cGVHD) at 1 year from 35.2% to 13.3% in ...
Hosted on MSN
How Graft-Versus-Host Disease (GvHD) Is Treated
Graft-versus-host disease (GvHD) is a complication of a stem cell or bone marrow transplant in which transplanted cells from a donor triggers an abnormal immune response in the recipient, causing the ...
Allogeneic HSCT is frequently complicated by acute GVHD (~50%) and chronic GVHD (30%–70%), with steroid-refractory disease representing a major unmet need despite ruxolitinib availability. CK0802 ...
A bone marrow or stem cell transplant can be life-saving for those diagnosed with some blood cancers, but many don’t know that it can also cause other health issues that may last long after treatment ...
The addition of a drug commonly used to treat arthritis may reduce the risk of graft-versus-host-disease in patients who underwent haploidentical allogeneic stem cell transplant. For many blood ...
PLYMOUTH MEETING, PA [January 10, 2022] — The National Comprehensive Cancer Network (NCCN ®) today announced the publication of new NCCN Guidelines for Patients ®: Graft-Versus-Host Disease (GVHD).
In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against graft-versus-host disease (GVHD). A ...
The National Comprehensive Cancer Network (NCCN ®) today announced the publication of new NCCN Guidelines for Patients ®: Graft-Versus-Host Disease (GVHD). GVHD is a complication that occurs after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results